{"PubmedArticle": [{"MedlineCitation": {"SpaceFlightMission": [], "OtherID": [], "InvestigatorList": [], "OtherAbstract": [], "CitationSubset": ["IM"], "KeywordList": [], "GeneralNote": [], "PMID": "18974148", "DateCompleted": {"Year": "2008", "Month": "12", "Day": "08"}, "DateRevised": {"Year": "2022", "Month": "04", "Day": "09"}, "Article": {"ArticleDate": [], "Language": ["eng"], "ELocationID": ["10.1158/0008-5472.CAN-08-2494"], "Journal": {"ISSN": "1538-7445", "JournalIssue": {"Volume": "68", "Issue": "21", "PubDate": {"Year": "2008", "Month": "Nov", "Day": "01"}}, "Title": "Cancer research", "ISOAbbreviation": "Cancer Res"}, "ArticleTitle": "Plumbagin, a medicinal plant-derived naphthoquinone, is a novel inhibitor of the growth and invasion of hormone-refractory prostate cancer.", "Pagination": {"StartPage": "9024", "EndPage": "9032", "MedlinePgn": "9024-32"}, "Abstract": {"AbstractText": ["Prostate cancer (PCa) is the second leading cause of cancer-related deaths in men. Hormone-refractory invasive PCa is the end stage and accounts for the majority of PCa patient deaths. We present here that plumbagin (PL), a quinoid constituent isolated from the root of the medicinal plant Plumbago zeylanica L., may be a potential novel agent in the control of hormone-refractory PCa. Specific observations are the findings that PL inhibited PCa cell invasion and selectively induced apoptosis in PCa cells but not in immortalized nontumorigenic prostate epithelial RWPE-1 cells. In addition, i.p. administration of PL (2 mg/kg body weight), beginning 3 days after ectopic implantation of hormone-refractory DU145 PCa cells, delayed tumor growth by 3 weeks and reduced both tumor weight and volume by 90%. Discontinuation of PL treatment in PL-treated mice for as long as 4 weeks did not result in progression of tumor growth. PL, at concentrations as low as 5 micromol/L, inhibited in both cultured PCa cells and DU145 xenografts (a) the expression of protein kinase Cepsilon (PKCepsilon), phosphatidylinositol 3-kinase, phosphorylated AKT, phosphorylated Janus-activated kinase-2, and phosphorylated signal transducer and activator of transcription 3 (Stat3); (b) the DNA-binding activity of transcription factors activator protein-1, nuclear factor-kappaB, and Stat3; and (c) Bcl-xL, cdc25A, and cyclooxygenase-2 expression. The results indicate for the first time, using both in vitro and in vivo preclinical models, that PL inhibits the growth and invasion of PCa. PL inhibits multiple molecular targets including PKCepsilon, a predictive biomarker of PCa aggressiveness. PL may be a novel agent for therapy of hormone-refractory PCa."]}, "AuthorList": [{"AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Human Oncology, School of Medicine and Public Health, University of Wisconsin, Madison, Wisconsin 53792, USA."}], "Identifier": [], "LastName": "Aziz", "ForeName": "Moammir H", "Initials": "MH"}, {"AffiliationInfo": [], "Identifier": [], "LastName": "Dreckschmidt", "ForeName": "Nancy E", "Initials": "NE"}, {"AffiliationInfo": [], "Identifier": [], "LastName": "Verma", "ForeName": "Ajit K", "Initials": "AK"}], "GrantList": [{"GrantID": "R01 CA035368", "Acronym": "CA", "Agency": "NCI NIH HHS", "Country": "United States"}, {"GrantID": "R01 CA035368-23", "Acronym": "CA", "Agency": "NCI NIH HHS", "Country": "United States"}, {"GrantID": "CA35368", "Acronym": "CA", "Agency": "NCI NIH HHS", "Country": "United States"}], "PublicationTypeList": ["Journal Article", "Research Support, N.I.H., Extramural", "Research Support, U.S. Gov't, Non-P.H.S."]}, "MedlineJournalInfo": {"Country": "United States", "MedlineTA": "Cancer Res", "NlmUniqueID": "2984705R", "ISSNLinking": "0008-5472"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "DNA Primers"}, {"RegistryNumber": "0", "NameOfSubstance": "Naphthoquinones"}, {"RegistryNumber": "YAS4TBQ4OQ", "NameOfSubstance": "plumbagin"}], "MeshHeadingList": [{"QualifierName": [], "DescriptorName": "Animals"}, {"QualifierName": ["drug effects"], "DescriptorName": "Apoptosis"}, {"QualifierName": [], "DescriptorName": "Base Sequence"}, {"QualifierName": ["drug effects"], "DescriptorName": "Cell Division"}, {"QualifierName": [], "DescriptorName": "DNA Primers"}, {"QualifierName": [], "DescriptorName": "Electrophoretic Mobility Shift Assay"}, {"QualifierName": [], "DescriptorName": "Humans"}, {"QualifierName": [], "DescriptorName": "Immunohistochemistry"}, {"QualifierName": [], "DescriptorName": "Male"}, {"QualifierName": [], "DescriptorName": "Mice"}, {"QualifierName": [], "DescriptorName": "Mice, Nude"}, {"QualifierName": ["pharmacology"], "DescriptorName": "Naphthoquinones"}, {"QualifierName": [], "DescriptorName": "Neoplasm Invasiveness"}, {"QualifierName": ["chemistry"], "DescriptorName": "Plants, Medicinal"}, {"QualifierName": ["pathology"], "DescriptorName": "Prostatic Neoplasms"}]}, "PubmedData": {"ReferenceList": [{"ReferenceList": [], "Reference": [{"Citation": "Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005. CA Cancer J Clin. 2005;55:10\u201330.", "ArticleIdList": ["15661684"]}, {"Citation": "Edwards J, Bartlett JM. The androgen receptor and signal-transduction pathways in hormone-refractory prostate cancer. Part 2: Androgen-receptor cofactors and bypass pathways. BJU Int. 2005;95:1327\u201335.", "ArticleIdList": ["15892826"]}, {"Citation": "Zhou J, Scholes J, Hsieh JT. Signal transduction targets in androgen-independent prostate cancer. Cancer Metastasis Rev. 2001;20:351\u201362.", "ArticleIdList": ["12085971"]}, {"Citation": "Silvestris N, Leone B, Numico G, et al. Present status and perspectives in the treatment of hormone-refractory prostate cancer. Oncology. 2005;69:273\u201382.", "ArticleIdList": ["16282706"]}, {"Citation": "Chau CH, Figg WD. Molecular and phenotypic heterogeneity of metastatic prostate cancer. Cancer Biol Ther. 2005;4:166\u20137.", "ArticleIdList": ["15738648"]}, {"Citation": "Quinn DI, Henshall SM, Sutherland RL. Molecular markers of prostate cancer outcome. Eur J Cancer. 2005;41:858\u201387.", "ArticleIdList": ["15808955"]}, {"Citation": "Sandur SK, Ichikawa H, Sethi G, et al. Plumbagin (5-hydroxy-2-methyl-1,4-naphthoquinone) suppresses NF-kappaB activation and NF-kappaB-regulated gene products through modulation of p65 and IkappaBalpha kinase activation, leading to potentiation of apoptosis induced by cytokine and chemotherapeutic agents. J Biol Chem. 2006;281:17023\u201333.", "ArticleIdList": ["16624823"]}, {"Citation": "Sugie S, Okamoto K, Rahman KM, et al. Inhibitory effects of plumbagin and juglone on azoxymethane-induced intestinal carcinogenesis in rats. Cancer Lett. 1998;127:177\u201383.", "ArticleIdList": ["9619875"]}, {"Citation": "Kuo PL, Hsu YL, Cho CY. Plumbagin induces G2-M arrest and autophagy by inhibiting the AKT/mammalian target of rapamycin pathway in breast cancer cells. Mol Cancer Ther. 2006;5:3209\u201321.", "ArticleIdList": ["17172425"]}, {"Citation": "Hsu YL, Cho CY, Kuo PL, et al. Plumbagin (5-hydroxy-2-methyl-1,4-naphthoquinone) induces apoptosis and cell cycle arrest in A549 cells through p53 accumulation via c-Jun NH2-terminal kinase-mediated phosphorylation at serine 15 in vitro and in vivo. J Pharmacol Exp Ther. 2006;318:484\u201394.", "ArticleIdList": ["16632641"]}, {"Citation": "Wang CC, Chiang YM, Sung SC, et al. Plumbagin induces cell cycle arrest and apoptosis through reactive oxygen species/c-Jun N-terminal kinase pathways in human melanoma A375.S2 cells. Cancer Lett. 2008;259:82\u201398.", "ArticleIdList": ["18023967"]}, {"Citation": "Powolny AA, Singh SV. Plumbagin-induced Apoptosis in Human Prostate Cancer Cells is Associated with Modulation of Cellular Redox Status and Generation of Reactive Oxygen Species. Pharm Res. 2008", "ArticleIdList": ["18213451"]}, {"Citation": "Rajesh D, Schell K, Verma AK. Ras mutation, irrespective of cell type and p53 status, determines a cell's destiny to undergo apoptosis by okadaic acid, an inhibitor of protein phosphatase 1 and 2A. Mol Pharmacol. 1999;56:515\u201325.", "ArticleIdList": ["10462539"]}, {"Citation": "Aziz MH, Manoharan HT, Church DR, et al. Protein kinase Cepsilon interacts with signal transducers and activators of transcription 3 (Stat3), phosphorylates Stat3Ser727, and regulates its constitutive activation in prostate cancer. Cancer Res. 2007;67:8828\u201338.", "ArticleIdList": ["17875724"]}, {"Citation": "Bussard KM, Gay CV, Mastro AM. The bone microenvironment in metastasis; what is special about bone? Cancer Metastasis Rev. 2008;27:41\u201355.", "ArticleIdList": ["18071636"]}, {"Citation": "Keller ET, Dai J, Escara-Wilke J, et al. New trends in the treatment of bone metastasis. J Cell Biochem. 2007;102:1095\u2013102.", "ArticleIdList": ["17955492"]}, {"Citation": "Kingsley LA, Fournier PG, Chirgwin JM, et al. Molecular biology of bone metastasis. Mol Cancer Ther. 2007;6:2609\u201317.", "ArticleIdList": ["17938257"]}, {"Citation": "Valdespino V, Tsagozis P, Pisa P. Current perspectives in the treatment of advanced prostate cancer. Med Oncol. 2007;24:273\u201386.", "ArticleIdList": ["17873302"]}, {"Citation": "Gupta S. Prostate cancer chemoprevention: current status and future prospects. Toxicol Appl Pharmacol. 2007;224:369\u201376.", "ArticleIdList": ["17189645"]}, {"Citation": "Patel D, Shukla S, Gupta S. Apigenin and cancer chemoprevention: progress, potential and promise (review) Int J Oncol. 2007;30:233\u201345.", "ArticleIdList": ["17143534"]}, {"Citation": "Adhami VM, Mukhtar H. Polyphenols from green tea and pomegranate for prevention of prostate cancer. Free Radic Res. 2006;40:1095\u2013104.", "ArticleIdList": ["17015254"]}, {"Citation": "Bemis DL, Katz AE, Buttyan R. Clinical trials of natural products as chemopreventive agents for prostate cancer. Expert Opin Investig Drugs. 2006;15:1191\u2013200.", "ArticleIdList": ["16989596"]}, {"Citation": "Srinivas G, Annab LA, Gopinath G, et al. Antisense blocking of BRCA1 enhances sensitivity to plumbagin but not tamoxifen in BG-1 ovarian cancer cells. Mol Carcinog. 2004;39:15\u201325.", "ArticleIdList": ["14694444"]}, {"Citation": "Srinivas P, Gopinath G, Banerji A, et al. Plumbagin induces reactive oxygen species, which mediate apoptosis in human cervical cancer cells. Mol Carcinog. 2004;40:201\u201311.", "ArticleIdList": ["15264212"]}, {"Citation": "Kawiak A, Piosik J, Stasilojc G, et al. Induction of apoptosis by plumbagin through reactive oxygen species-mediated inhibition of topoisomerase II. Toxicol Appl Pharmacol. 2007;223:267\u201376.", "ArticleIdList": ["17618663"]}, {"Citation": "Shankar S, Ganapathy S, Chen Q, et al. Curcumin sensitizes TRAIL-resistant xenografts: molecular mechanisms of apoptosis, metastasis and angiogenesis. Mol Cancer. 2008;7:16.", "ArticleIdList": ["PMC2249593", "18226269"]}, {"Citation": "Kong D, Li Y, Wang Z, et al. Inhibition of angiogenesis and invasion by 3,3\u2032-diindolylmethane is mediated by the nuclear factor-kappaB downstream target genes MMP-9 and uPA that regulated bioavailability of vascular endothelial growth factor in prostate cancer. Cancer Res. 2007;67:3310\u20139.", "ArticleIdList": ["17409440"]}, {"Citation": "Adhami VM, Ahmad N, Mukhtar H. Molecular targets for green tea in prostate cancer prevention. J Nutr. 2003;133:2417S\u201324S.", "ArticleIdList": ["12840218"]}, {"Citation": "Griner EM, Kazanietz MG. Protein kinase C and other diacylglycerol effectors in cancer. Nat Rev Cancer. 2007;7:281\u201394.", "ArticleIdList": ["17384583"]}, {"Citation": "Mellor H, Parker PJ. The extended protein kinase C superfamily. Biochem J. 1998;332(Pt 2):281\u201392.", "ArticleIdList": ["PMC1219479", "9601053"]}, {"Citation": "Newton AC. Protein kinase C: structural and spatial regulation by phosphorylation, cofactors, and macromolecular interactions. Chem Rev. 2001;101:2353\u201364.", "ArticleIdList": ["11749377"]}, {"Citation": "Mochly-Rosen D, Kauvar LM. Modulating protein kinase C signal transduction. Adv Pharmacol. 1998;44:91\u2013145.", "ArticleIdList": ["9547885"]}, {"Citation": "Basu A, Sivaprasad U. Protein kinase Cepsilon makes the life and death decision. Cell Signal. 2007;19:1633\u201342.", "ArticleIdList": ["PMC1986651", "17537614"]}, {"Citation": "Cornford P, Evans J, Dodson A, et al. Protein kinase C isoenzyme patterns characteristically modulated in early prostate cancer. Am J Pathol. 1999;154:137\u201344.", "ArticleIdList": ["PMC1853450", "9916928"]}, {"Citation": "Wu D, Foreman TL, Gregory CW, et al. Protein kinase cepsilon has the potential to advance the recurrence of human prostate cancer. Cancer Res. 2002;62:2423\u20139.", "ArticleIdList": ["11956106"]}, {"Citation": "Wu D, Thakore CU, Wescott GG, et al. Integrin signaling links protein kinase Cepsilon to the protein kinase B/Akt survival pathway in recurrent prostate cancer cells. Oncogene. 2004;23:8659\u201372.", "ArticleIdList": ["15467757"]}, {"Citation": "Wu D, Terrian DM. Regulation of caveolin-1 expression and secretion by a protein kinase cepsilon signaling pathway in human prostate cancer cells. J Biol Chem. 2002;277:40449\u201355.", "ArticleIdList": ["12185081"]}, {"Citation": "Huang HF, Murphy TF, Shu P, et al. Stable expression of constitutively-activated STAT3 in benign prostatic epithelial cells changes their phenotype to that resembling malignant cells. Mol Cancer. 2005;4:2.", "ArticleIdList": ["PMC546221", "15647107"]}, {"Citation": "Alvarez JV, Febbo PG, Ramaswamy S, et al. Identification of a genetic signature of activated signal transducer and activator of transcription 3 in human tumors. Cancer Res. 2005;65:5054\u201362.", "ArticleIdList": ["15958548"]}, {"Citation": "Burke WM, Jin X, Lin HJ, et al. Inhibition of constitutively active Stat3 suppresses growth of human ovarian and breast cancer cells. Oncogene. 2001;20:7925\u201334.", "ArticleIdList": ["11753675"]}, {"Citation": "Ni Z, Lou W, Leman ES, et al. Inhibition of constitutively activated Stat3 signaling pathway suppresses growth of prostate cancer cells. Cancer Res. 2000;60:1225\u20138.", "ArticleIdList": ["10728680"]}, {"Citation": "Fernandes A, Hamburger AW, Gerwin BI. ErbB-2 kinase is required for constitutive stat 3 activation in malignant human lung epithelial cells. Int J Cancer. 1999;83:564\u201370.", "ArticleIdList": ["10508495"]}, {"Citation": "Kobielak A, Fuchs E. Links between alpha-catenin, NF-kappaB, and squamous cell carcinoma in skin. Proc Natl Acad Sci U S A. 2006;103:2322\u20137.", "ArticleIdList": ["PMC1413714", "16452166"]}, {"Citation": "Levy DE, Darnell JE., Jr. Stats: transcriptional control and biological impact. Nat Rev Mol Cell Biol. 2002;3:651\u201362.", "ArticleIdList": ["12209125"]}, {"Citation": "Chan KS, Sano S, Kiguchi K, et al. Disruption of Stat3 reveals a critical role in both the initiation and the promotion stages of epithelial carcinogenesis. J Clin Invest. 2004;114:720\u20138.", "ArticleIdList": ["PMC514583", "15343391"]}, {"Citation": "McJilton MA, Van Sikes C, Wescott GG, et al. Protein kinase Cepsilon interacts with Bax and promotes survival of human prostate cancer cells. Oncogene. 2003;22:7958\u201368.", "ArticleIdList": ["12970744"]}, {"Citation": "Suzuki H, Ueda T, Ichikawa T, et al. Androgen receptor involvement in the progression of prostate cancer. Endocr Relat Cancer. 2003;10:209\u201316.", "ArticleIdList": ["12790784"]}, {"Citation": "Danielpour D. Functions and regulation of transforming growth factor-beta (TGF-beta) in the prostate. Eur J Cancer. 2005;41:846\u201357.", "ArticleIdList": ["15808954"]}, {"Citation": "Craft N, Shostak Y, Carey M, et al. A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. Nat Med. 1999;5:280\u20135.", "ArticleIdList": ["10086382"]}, {"Citation": "Chen J, Deng F, Singh SV, et al. Protein kinase D3 (PKD3) contributes to prostate cancer cell growth and survival through a PKCepsilon/PKD3 pathway downstream of Akt and ERK 1/2. Cancer Res. 2008;68:3844\u201353.", "ArticleIdList": ["18483269"]}]}], "History": [{"Year": "2008", "Month": "11", "Day": "1", "Hour": "9", "Minute": "0"}, {"Year": "2008", "Month": "12", "Day": "17", "Hour": "9", "Minute": "0"}, {"Year": "2008", "Month": "11", "Day": "1", "Hour": "9", "Minute": "0"}, {"Year": "2009", "Month": "11", "Day": "1"}], "PublicationStatus": "ppublish", "ArticleIdList": ["18974148", "NIHMS77327", "PMC2584362", "10.1158/0008-5472.CAN-08-2494", "68/21/9024"]}}], "PubmedBookArticle": []}